DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
BGG492 is an investigational drug.
There have been 10 clinical trials for BGG492. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2009.
The most common disease conditions in clinical trials are Seizures, Migraine Disorders, and Epilepsy. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and [disabled in preview].
Recent Clinical Trials for BGG492
|Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis||Novartis Pharmaceuticals||Phase 2|
|A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention||Novartis Pharmaceuticals||Phase 2|
|Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492||Novartis Pharmaceuticals||Phase 2|